Publication | Closed Access

Clinical Protocol: Administration of Neomycin Resistance Gene-Marked EBV-Specific Cytotoxic T-Lymphocytes as Therapy for Patients Receiving a Bone Marrow Transplant for Relapsed EBV-Positive Hodgkin Disease.

Cell TherapyTransplantationEbv-positive Hodgkin DiseaseBone Marrow TransplantHematologyImmunologyPathologyAutoimmunityClinical ProtocolAdult T-cell Leukemia-lymphomaImmunotherapyMedicineCell Transplantation